Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial

Ramesh K. Ramanathan,Chandra P. Belani,Deepti A. Singh,Michael Tanaka,Heinz-Josef Lenz,Yun Yen,Hedy L. Kindler,Syma Iqbal,Jeff Longmate,David R. Gandara

Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial

2006

Ramesh K. Ramanathan
Chandra P. Belani
Deepti A. Singh
Michael Tanaka
Heinz-Josef Lenz
Yun Yen
Hedy L. Kindler
Syma Iqbal
Jeff Longmate
David R. Gandara

4010 Background: Advanced BTC (gallbladder, bile duct) and HCC respond poorly to systemic chemotherapy. Lapatinib is an oral inhibitor of EGFR and Her/2-neu with evidence of activity in a number of...

Keywords:

Tyrosine kinase
Cancer
Epidermal growth factor receptor
HER2/neu
Lapatinib
Internal medicine
Endocrinology
Medicine
Gallbladder
Phases of clinical research
Oncology
Bile duct
dual inhibitor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations